<SEC-DOCUMENT>0001728117-25-000037.txt : 20250515
<SEC-HEADER>0001728117-25-000037.hdr.sgml : 20250515
<ACCEPTANCE-DATETIME>20250515160216
ACCESSION NUMBER:		0001728117-25-000037
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250515
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250515
DATE AS OF CHANGE:		20250515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gossamer Bio, Inc.
		CENTRAL INDEX KEY:			0001728117
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				475461709
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38796
		FILM NUMBER:		25952450

	BUSINESS ADDRESS:	
		STREET 1:		3115 MERRYFIELD ROW
		STREET 2:		SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 684-1300

	MAIL ADDRESS:	
		STREET 1:		3115 MERRYFIELD ROW
		STREET 2:		SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>goss-20250515.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ca7355fb-477f-4166-aa6f-b987bb60da99,g:361c98ea-359c-4434-9eae-780946a94c06,d:e7e2a927ae2644e2b6a248c7606bf28a-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>goss-20250515</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001728117</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="goss-20250515.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-15</xbrli:startDate><xbrli:endDate>2025-05-15</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie7e2a927ae2644e2b6a248c7606bf28a_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"/><td style="width:27.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.782%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"/><td style="width:27.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.782%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 15, 2025</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"/><td style="width:27.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.782%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">GOSSAMER BIO, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"/><td style="width:27.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.782%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:32.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38796</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">47-5461709</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">3115 Merryfield Row, Suite 120</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">92121</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">684-1300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"/><td style="width:27.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.782%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.468%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.468%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.468%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.468%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:36.532%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.862%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.862%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">GOSS</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;15, 2025, Gossamer Bio, Inc. (the &#8220;Company&#8221;) issued a press release reporting its financial results for the quarter ended March&#160;31, 2025.&#160;The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release attached as Exhibit&#160;99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, whether made before or after the date hereof, except as&#160;expressly set forth by specific reference in such filing to this Current Report on Form 8-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="goss-20250515xexx991.htm">Press Release</a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> dated May&#160;15, 2025 </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;101 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.410%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GOSSAMER BIO, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May&#160;15, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Bryan Giraudo</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bryan Giraudo</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Operating Officer</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>goss-20250515xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ib9068bba950a450b910af4999bf15d88_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-top:10pt"><img alt="newgosslogoa.jpg" src="newgosslogoa.jpg" style="height:96px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"></div><div style="text-align:center"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">- Enrollment  Completion for Ongoing Registrational PROSERA Phase 3 Study in PAH Expected in Early June&#59; New Patient Screening Closed -</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">- Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 -</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">- To Date, Blinded Baseline Characteristics Align with Intended Study Population -</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">- First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the Fourth Quarter of 2025 -</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">-</font><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> Cash, cash equivalents and marketable securities totaled </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">$258</font><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> million </font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">as of March&#160;31, 2025 -</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SAN DIEGO&#8212;(BUSINESS WIRE)&#8212;</font><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> May&#160;15, 2025</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#8212; </font><font style="background-color:#ffffff;color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Gossamer Bio, Inc.</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> (Nasdaq&#58; GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March&#160;31, 2025, and announced the closure of new patient screening for the ongoing registrational Phase 3 PROSERA Study in PAH patients.</font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#34;I am incredibly proud to announce that, following the recent closing of new patient screening, we are just weeks away from fully enrolling the PROSERA Phase 3 Study in PAH,&#34; said Faheem Hasnain, Chairman, Co-Founder, and CEO of Gossamer Bio. </font></div><div style="margin-bottom:12pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#34;This achievement is the result of our team's unwavering dedication, tireless effort, and steadfast commitment to our mission. We expect to publicly announce topline data from this pivotal study in February of 2026. Enrolling the appropriate patients for this study was of paramount importance, and the baseline characteristics of those who have been randomized to date demonstrate that our diligence and focus on study quality has paid off. This reinforces our optimism for meaningful results and brings us one step closer to the potential of having a new, first-in-class therapy for patients with PAH.&#8221;</font></div><div><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Medical Officer Dr. Richard Aranda added, &#34;We are also delighted to unveil the clinical trial design for the Phase 3 SERANATA Study in PH-ILD, a landmark moment in our pursuit to address unmet patient need. A product of close collaboration and alignment with global regulatory authorities, including the FDA and EMA, this study represents a groundbreaking effort to offer new hope to patients with PH-ILD.&#34;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Seralutinib (GB002)&#58; Inhaled PDGFR, CSF1R and c-KIT Inhibitor</font></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;On May 14th, we closed new patient screening for the ongoing PROSERA Study in Functional Class II and III PAH patients. To date, 343 patients have been enrolled or are scheduled to randomize into the PROSERA Study. With the additional patients currently in screening, we expect to complete enrollment with over 350 PAH patients in early June. </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o&#160;&#160;&#160;&#160;The Phase 3 PROSERA Study is a double-blind, placebo-controlled, global registrational clinical trial evaluating seralutinib in PAH patients, on top of background PAH therapy. Patients are assigned 1&#58;1 to either the seralutinib or placebo arms. Patients receive blinded treatment for up to 48 weeks.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o&#160;&#160;&#160;&#160;The primary endpoint of the PROSERA Study is change in six-minute walk distance (6MWD) from baseline as compared to placebo at week 24. Included in the key secondary endpoints is time to clinical worsening, as compared to placebo, up to week 48. In addition to other secondary and exploratory endpoints, safety and tolerability will be evaluated.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o&#160;&#160;&#160;&#160;The patient population enrolled in PROSERA aligns with the target demographic, as evidenced by available baseline characteristics. The PROSERA Study utilizes enrichment criteria, including the REVEAL Lite 2 Risk Score and other criteria, to identify patients more likely to show a greater magnitude of effect on 6MWD at week 24, as informed by the Phase 2 TORREY study.  </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o&#160;&#160;&#160;&#160;Seralutinib Clinical Trial Baseline Characteristics&#58; Phase 3 PROSERA Study* v. Phase 2 TORREY Study</font></div><div style="margin-bottom:6pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:-27pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                   </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.570%"><tr><td style="width:1.0%"></td><td style="width:47.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.834%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PROSERA Phase 3*</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TORREY Phase 2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Study Participants</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n &#61; 324</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">(target&#58; 350)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n &#61; 86</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Mean 6MWD</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">376 meters</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">408 meters</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Mean NT-proBNP</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">986 ng&#47;L</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">628 ng&#47;L</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Functional Class III Patients</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">239 (74%)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36 (42%)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Geographic Distribution</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:7pt;font-weight:400;line-height:112%">North America&#58; 61 (19%)</font></div><div style="margin-bottom:0.08pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Rest of World&#58; 263 (81%)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:7pt;font-weight:400;line-height:112%">North America&#58; 59 (69%)</font></div><div style="margin-bottom:0.08pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Rest of World&#58; 27 (31%)</font></div></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">*Characteristics shown are for the first 324 patients enrolled in the PROSERA Study, and all PROSERA Study percentages are out of 324. Given the patients scheduled to randomize and those still in screening, we expect to complete full enrollment in early June. Final baseline characteristics for the PROSERA Study are subject to change.</font></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o&#160;&#160;&#160;&#160;We expect to announce topline results from the ongoing Phase 3 PROSERA Study in February 2026. </font></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We expect to activate clinical sites for the global, registrational Phase 3 SERANATA Study in PH-ILD patients in the fourth quarter of 2025. </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o&#160;&#160;&#160;&#160;Achieved alignment on study design and endpoints with global regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o&#160;&#160;&#160;&#160;The planned SERANATA Study will be a 24-week, randomized, double-blind, placebo-controlled, global clinical trial in PH-ILD patients. Approximately 480 patients will be randomized 1&#58;1&#58;1 to receive either 90mg seralutinib twice-daily, 120mg seralutinib twice-daily or placebo. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o&#160;&#160;&#160;&#160;The primary endpoint of the SERANATA Study is change in 6MWD from baseline as compared to placebo at week 24. Key secondary endpoints will include time to clinical worsening and change from baseline in forced vital capacity (FVC).</font></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;     One poster related to seralutinib will be presented at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 16th through 21st, in San Francisco, California.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o&#160;&#160;&#160;&#160;Poster Presentation </font></div><div style="margin-bottom:3pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9642;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.78pt">Title&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">Seralutinib in Pulmonary Arterial Hypertension&#58; Exploring Mechanisms of Reverse Remodeling Versus Vasodilation</font></div><div style="margin-bottom:3pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9642;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.78pt">Poster Number&#58; P920</font></div><div style="margin-bottom:3pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9642;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.78pt">Session&#58; A76 Finger on the Pulse&#58; Cardiopulmonary Dysfunction in Lung Disease</font></div><div style="margin-bottom:3pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9642;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.78pt">Date&#58; Sunday, May 18th</font></div><div style="margin-bottom:3pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9642;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.78pt">Time&#58; 11&#58;30am &#8211; 1&#58;15pm PDT</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9642;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.78pt">Location&#58; Area G, Hall F (North Building, Exhibition Level), Moscone Center</font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">o&#160;&#160;&#160;&#160;Following its presentation at the ATS 2025 International Conference, the poster will also be made available on the &#8220;Posters &#38; Publications&#8221; section of the Gossamer Bio website at gossamerbio.com&#47;science&#47;posters-and-presentations&#47;.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Financial Results for Quarter Ended March&#160;31, 2025</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Cash, Cash Equivalents and Marketable Securities</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Cash, cash equivalents and marketable securities as of March&#160;31, 2025, were $257.9 million. We expect the combination of current cash, cash equivalents and marketable securities will be sufficient to fund our operating and capital expenditures into the</font><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> first half of 2027.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:13.13pt">Revenue from Sale of Licenses and from Contracts with Collaborators</font><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#58; For the quarter ended </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">March&#160;31, 2025</font><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:125%">, revenue associated with our collaboration with Chiesi was </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$9.9 million, including $6.6 million of cost reimbursement revenue.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.13pt">Research and Development (R&#38;D) Expenses</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; For the quarter ended March&#160;31, 2025, R&#38;D expenses were </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$38.0 million</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, compared to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$32.4 million</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the same period in 2024.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">General and Administrative (G&#38;A) Expenses</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; For the quarter ended March&#160;31, 2025, G&#38;A expenses were </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$8.7 million</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, compared to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$9.6 million</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the same period in 2024. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Net Loss</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Net loss for the quarter ended March&#160;31, 2025, was </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$36.6 million</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, or </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$0.16</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> basic net loss per share, compared to a net loss of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$41.9 million</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, or </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$0.19</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> basic net loss per share, for the same period in 2024.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:10pt"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Conference Call and Webcast</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Gossamer&#8217;s management team will host a conference call and live audio webcast at 4&#58;30 p.m. ET today, Thursday, May 15th, to discuss its first quarter 2025 financial results and business update.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The live audio webcast may be accessed through the &#8220;Events &#47; Presentations&#8221; page in the &#8220;Investors&#8221; section of the Company's website at gossamerbio.com. Alternatively, the conference call may be accessed through the following&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Domestic Dial-in Number&#58; (800) 285-6670</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">International Dial-in Number&#58; (713) 481-0091</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Live Webcast&#58; https&#58;&#47;&#47;edge.media-server.com&#47;mmc&#47;p&#47;m5ahx8qm</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">A replay of the audio webcast will be available for 30 days on the &#8220;Investors&#8221; section of the Company's website, gossamerbio.com.</font></div><div style="margin-bottom:0.08pt"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:125%">About&#160;Gossamer Bio</font></div><div style="margin-top:10pt"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.</font></div><div style="margin-top:10pt"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company&#8217;s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding&#58; the anticipated timing of enrollment completion and a data readout from our Phase 3 PROSERA Study&#59; the potential or likelihood for a meaningful data readout from our PROSERA Study&#59; the development potential of seralutinib&#59; the anticipated timing on commencing a Phase 3 clinical trial in PH-ILD&#59; and the expected timeframe for funding our operating plan with current cash, cash equivalents and marketable securities. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer&#8217;s business, including, without limitation&#58; potential delays in the commencement, enrollment and completion of clinical trials&#59; disruption to our operations from unexpected events, including clinical trial delays&#59; the Company&#8217;s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing&#59; the results of preclinical studies and early clinical trials are not necessarily predictive of future results&#59; the success of Gossamer&#8217;s clinical trials and preclinical studies for seralutinib&#59; regulatory developments in the United States and foreign countries&#59; unexpected adverse side effects or inadequate efficacy of seralutinib that may limit its development, regulatory approval and&#47;or commercialization, or may result in clinical holds, recalls or product liability claims&#59; Gossamer&#8217;s ability to obtain and maintain intellectual property protection for seralutinib&#59; Gossamer&#8217;s ability to comply with its obligations in collaboration agreements with third parties or the agreements under which it licenses intellectual property rights from third parties&#59; unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may adversely affect our business and financial condition and the broader economy and biotechnology industry&#59; Gossamer may use its capital resources sooner than it expects&#59; and other risks described in the Company&#8217;s prior press releases and the Company&#8217;s filings with the Securities and Exchange Commission (SEC), including under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Gossamer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div id="ib9068bba950a450b910af4999bf15d88_4"></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Gossamer Bio Statement of Operations</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Condensed Consolidated Statement of Operations</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:125%">(in thousands, except share and per share amounts)</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:125%">(unaudited)</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.993%"><tr><td style="width:1.0%"></td><td style="width:53.301%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:21.247%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.702%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Revenue from contracts with collaborators</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,889&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenue</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,889&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,041&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,392&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,658&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,567&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,699&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,959&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss from operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(36,810)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(41,959)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">344&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,746)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,129)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,624&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,816&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(36,638)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(41,928)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.16)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.19)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">226,818,051&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225,735,236&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheet</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:125%">(in thousands)</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">BALANCE SHEET DATA&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257,934&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294,518&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Working capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227,252&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">264,878&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">280,589&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">315,292&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">286,839&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">285,800&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,305,206)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,268,568)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total stockholders' equity (deficit)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,250)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,492&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:5pt"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For Investors and Media&#58; </font></div><div style="margin-bottom:0.08pt"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Bryan Giraudo, Chief Financial Officer &#38; Chief Operating Officer</font></div><div style="margin-bottom:0.08pt"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gossamer Bio Investor Relations</font></div><div style="margin-bottom:0.08pt"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ir&#64;gossamerbio.com</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>goss-20250515.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ca7355fb-477f-4166-aa6f-b987bb60da99,g:361c98ea-359c-4434-9eae-780946a94c06-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:goss="http://www.gossamerbio.com/20250515" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.gossamerbio.com/20250515">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="goss-20250515_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="goss-20250515_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.gossamerbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>goss-20250515_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ca7355fb-477f-4166-aa6f-b987bb60da99,g:361c98ea-359c-4434-9eae-780946a94c06-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_34e1b63c-14b6-423e-9135-d031608750c0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e9bea69c-f742-4828-9c50-67822a47e0c1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6a17a734-71a5-478c-ae62-4685e3cbd7a6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_102152d7-0d0a-4bdf-a0c9-d3788663d44a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_157fa143-2731-4d25-9f1c-3e94a764be7e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_c89a4703-cdee-4191-81f7-79cb09eaf5d2_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1436f3a1-c4d7-4ec8-a286-b0f6b8cfb1ea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a0a983aa-b611-4152-bc5a-df7f8708830c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_0c0287e6-f044-4216-ba0b-d640dd1761ff_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c6a36589-afa2-4936-83b0-dfe7991c3fdb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_472f8a4b-040e-4346-8638-6ca90adfd564_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_dd6a8f9f-8c0e-4747-aaa4-a4b19c0343c0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b9298292-0cca-4401-bbed-99aea8760609_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_476aef2c-f294-463d-991d-55d3d524e62f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_604045e5-d1de-4599-a506-814c8de7536a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b5cb4c69-dc16-4c91-a951-e883f6ae813b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_36ebd6ba-3123-403b-9d88-b54bae7333ec_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_477c3720-494e-4f80-9c05-5a05986d9160_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d396eb80-4b7e-4536-90fd-a6103736c441_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_189f1d2b-73f6-4f43-8efb-c71dcd2f62f8_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8ffdb6d5-bdda-422f-842d-f98623770041_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b4bf11e2-eff0-44be-ae88-52dd5d6257a2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>goss-20250515_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ca7355fb-477f-4166-aa6f-b987bb60da99,g:361c98ea-359c-4434-9eae-780946a94c06-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gossamerbio.com/role/Cover" xlink:type="simple" xlink:href="goss-20250515.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a7f618c2-6fd4-42c3-877a-4c13f1ae77ea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_DocumentType_a7f618c2-6fd4-42c3-877a-4c13f1ae77ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_dd616cd1-a628-4d9b-b259-2292e037e651" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_DocumentPeriodEndDate_dd616cd1-a628-4d9b-b259-2292e037e651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_dded6d1b-f637-407f-b9b4-2cb8cf64d3c6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_EntityRegistrantName_dded6d1b-f637-407f-b9b4-2cb8cf64d3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4dd2c8c0-25b8-41d8-887d-c815ffe99996" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4dd2c8c0-25b8-41d8-887d-c815ffe99996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fad705b7-6f21-486b-9089-30b478877b88" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_EntityFileNumber_fad705b7-6f21-486b-9089-30b478877b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6b1d4e59-4c4b-4a10-bc83-5753bd9ffd18" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_EntityTaxIdentificationNumber_6b1d4e59-4c4b-4a10-bc83-5753bd9ffd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3bda94d1-89bd-4b76-a80e-9d9d72d325b7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_EntityAddressAddressLine1_3bda94d1-89bd-4b76-a80e-9d9d72d325b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5790f795-cf67-404d-a421-cb08abe339f9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_EntityAddressCityOrTown_5790f795-cf67-404d-a421-cb08abe339f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4cbbe69a-f972-4075-8d24-97f02c12a6b7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_EntityAddressStateOrProvince_4cbbe69a-f972-4075-8d24-97f02c12a6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_068c5676-3ed9-469d-86a3-397a123c1261" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_EntityAddressPostalZipCode_068c5676-3ed9-469d-86a3-397a123c1261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a8caed9c-e8b9-4e9f-8941-3957eb1043dc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_CityAreaCode_a8caed9c-e8b9-4e9f-8941-3957eb1043dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f7b9e5c3-6f6f-46de-83d0-f3ec3cc11679" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_LocalPhoneNumber_f7b9e5c3-6f6f-46de-83d0-f3ec3cc11679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_1ace5af2-4f74-43c1-879d-ba77ebdc45d9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_WrittenCommunications_1ace5af2-4f74-43c1-879d-ba77ebdc45d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_644e585d-1f14-450c-8444-3f304fb404f5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_SolicitingMaterial_644e585d-1f14-450c-8444-3f304fb404f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_2520d157-fadd-4ab9-852b-89089b3f7568" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_PreCommencementTenderOffer_2520d157-fadd-4ab9-852b-89089b3f7568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_07d2379d-f1d5-4981-a12d-370faaf89cef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_07d2379d-f1d5-4981-a12d-370faaf89cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cd0a779c-7710-4370-ba7c-0389420da610" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_Security12bTitle_cd0a779c-7710-4370-ba7c-0389420da610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0b468708-1464-4fbf-9f73-909b25a62e35" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_TradingSymbol_0b468708-1464-4fbf-9f73-909b25a62e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a6b388d4-6946-4906-9c32-5710f7d23938" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_SecurityExchangeName_a6b388d4-6946-4906-9c32-5710f7d23938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_10be0821-539b-4028-99ee-ba3d965f07d9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_EntityEmergingGrowthCompany_10be0821-539b-4028-99ee-ba3d965f07d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1fb3dc66-1585-4e4c-80c0-65f4f4c7775a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_EntityCentralIndexKey_1fb3dc66-1585-4e4c-80c0-65f4f4c7775a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b563a5f7-e4ca-4ff8-8230-f7075f92747e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a354a39f-e8dc-4597-8dfb-29a899b7716d" xlink:to="loc_dei_AmendmentFlag_b563a5f7-e4ca-4ff8-8230-f7075f92747e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>newgosslogoa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 newgosslogoa.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !@ * # 2(  A$! Q$!_\0
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MU%4(=5BDVK(# YZ"3H?H>AJ_4V:W-$T]@HHHI#"BBB@ HHHH **** "BBB@
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M!1110 4455U"_@TNSFN[J016\*%Y';H * +5%>>P_%2XFM6U)/#5^VAKD_;
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211746BBBD6%%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 15, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 15,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GOSSAMER BIO, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5461709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3115 Merryfield Row, Suite 120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">684-1300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GOSS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001728117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $> KUI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( $> KUK4^ODY[P   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL].PS ,AU\%Y=XZ[2B'J,ME$R>0D)@$XA8E
MWA:M^:/$J-W;TY:M$X('X!C[E\^?);<Z"AT2OJ00,9'%?#>XSF>AXYH=B:(
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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M__HS M$N(=J702RX%BHB,QD1F/-:'ESI.'M-T]<IR3JHWDP:87;DA:^%G4!
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( $> KUJJQ"(6,P$  "("   /
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M              "  >$!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $> KUHD'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( $> KUIED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="goss-20250515.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="goss-20250515.htm">goss-20250515.htm</File>
    <File>goss-20250515.xsd</File>
    <File>goss-20250515_lab.xml</File>
    <File>goss-20250515_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "goss-20250515.htm": {
   "nsprefix": "goss",
   "nsuri": "http://www.gossamerbio.com/20250515",
   "dts": {
    "inline": {
     "local": [
      "goss-20250515.htm"
     ]
    },
    "schema": {
     "local": [
      "goss-20250515.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "goss-20250515_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "goss-20250515_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.gossamerbio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20250515.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20250515.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001728117-25-000037-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001728117-25-000037-xbrl.zip
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MFYR;CYC[71TNTPE8&1/!T2?OAS/29WXX13;!1N0>4M-^)P/NH^CBDG#,O_6
M?:*02#Z._8@&+(RE/R<2O#HYF*LOTP_"/A!PXNREA]GB^IPDAG$$H<$\:QL
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MUEOW9<F-X,*[+)9@@L7ZLPJ2MP14*X35D L*?EH'E3%( KP@_9E&-*EGLL?
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MT7A/\=-=5#N-W%FW1[5+R1]N5G_MN?E_4$L#!!0    ( $> KUKL+W#780(
M  ('   1    9V]S<RTR,#(U,#4Q-2YX<V3-5,ENVS 0O?LK6)U+2[)DV3)B
M!VB"  7<!6F"YE90U,@F(I$J2<7.WY>D13C*AKJGZD3-O#?+XPS/SO=-C1Y
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M$"$RV5B?K,WOM^SO2&V-.>>3^M5'TV7696C=XLD?OYU_E==Z+B!;+$NQD!7
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MN7UT^FKS3+;Z;Y6GK_X'4$L#!!0    ( $> KUHR%;A'L 8  .0P   5
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M/.5WVX_[B4A' X^8^+CGN!6SE(#SFH%0@KE@4@IT%RB\8'X0%W+J7.Q"VTE
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M.XOZF\43\<[PP-'>_0_=2_=0_-'>_P%02P,$%     @ 1X"O6BQ$T;[N'@
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MCZ52Y5 ;[N?^@(XWOIU\.KL$-7MU5K[4IG?A'^?7^!CC,"I84+4VD'J E8!
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MH[70,?7U +PVYL%[@S";\<>J92L5"'F%^7K?7+7<;?Z0/'8?^HD;7KQ=XFX
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MO0\  &=O<W,M,C R-3 U,34N>'-D4$L! A0#%     @ 1X"O6C+Q=10)"@
M?50  !4              ( !31(  &=O<W,M,C R-3 U,35?;&%B+GAM;%!+
M 0(4 Q0    ( $> KUHR%;A'L 8  .0P   5              "  8D<  !G
M;W-S+3(P,C4P-3$U7W!R92YX;6Q02P$"% ,4    " !'@*]:+$31ONX>  #=
M&@$ &               @ %L(P  9V]S<RTR,#(U,#4Q-7AE>'@Y.3$N:'1M
64$L%!@     %  4 2@$  )!"      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>goss-20250515_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="goss-20250515.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <startDate>2025-05-15</startDate>
            <endDate>2025-05-15</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001728117</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-05-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">GOSSAMER BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38796</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">47-5461709</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">3115 Merryfield Row, Suite 120</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">684-1300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">GOSS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
